WebDoctor Encyclopedia

Lymphomas

Castleman disease

Castleman disease is a group of rare lymph node disorders. Unicentric disease affects one node area and is usually cured by surgery. Multicentric disease causes fever, swelling and organ problems driven by IL-6 and is treated with siltuximab, rituximab or other medicines.

Medically reviewed Last reviewed October 27, 2026

What is Castleman disease?

Castleman disease is a rare disorder of the lymph nodes. It is not one disease but a group of related conditions that share the same changes in lymph node tissue under the microscope. It is named after Dr Benjamin Castleman, who first described it in the 1950s.

In Castleman disease, lymph nodes become enlarged because of an overgrowth of immune cells and blood vessels. In some forms, the immune system also releases large amounts of inflammatory signalling proteins, especially interleukin-6 (IL-6). This can make people very unwell, with fever, fluid build-up and organ damage.

Castleman disease is not a cancer, but it is treated by blood cancer (haematology) specialists, and some treatments are similar to those used for lymphoma. It is also linked with a higher risk of lymphoma and some other conditions (Dispenzieri and Fajgenbaum, 2020).

There are two main types:

  • Unicentric Castleman disease (UCD) affects one lymph node or one group of nodes. It usually causes few symptoms and is often cured by surgery.
  • Multicentric Castleman disease (MCD) affects several groups of lymph nodes around the body. It causes whole-body inflammation and needs medicines to control it.

Multicentric disease is further divided by its cause. Some cases are caused by the virus HHV-8, mainly in people with HIV. Others have no known cause and are called idiopathic multicentric Castleman disease (iMCD).

1. Key facts at a glance

Feature Details
Type of condition Rare lymph node disorder (lymphoproliferative disorder)
Is it cancer? No, but it is treated by haematologists and can be serious
Main types Unicentric (UCD) and multicentric (MCD)
Typical age UCD: often 30s-40s; iMCD: often 40s-50s; can occur at any age
Common sites Chest, neck, abdomen, armpits and groin
Key protein Interleukin-6 (IL-6), especially in multicentric forms
Main treatments Surgery for UCD; siltuximab or other medicines for iMCD; rituximab for HHV-8 MCD
Outlook Excellent for UCD; variable for multicentric forms

2. Causes and types

The causes of Castleman disease differ between types.

Type Cause Who is affected
Unicentric (UCD) Probably a clonal growth of supporting (stromal) cells in one lymph node region Young and middle-aged adults; children too
HHV-8-associated MCD Infection with human herpesvirus 8 (Kaposi sarcoma herpesvirus) Mostly people with HIV; also some people in areas where HHV-8 is common
Idiopathic MCD (iMCD) Unknown; thought to involve an overactive immune system Adults of any age, most often 40s-50s
iMCD-TAFRO A severe form of iMCD with sudden onset Adults; first described in Japan
POEMS-associated MCD Occurs with POEMS syndrome, a plasma cell disorder Adults with POEMS syndrome

The role of interleukin-6

IL-6 is a messenger protein that helps control inflammation. In multicentric Castleman disease, too much IL-6 (or, in HHV-8 MCD, a viral form of IL-6) drives many of the symptoms:

  • Fever and night sweats
  • Anaemia and low albumin
  • Fluid build-up in the body
  • Enlarged liver and spleen
  • High CRP and other markers of inflammation

This is why medicines that block IL-6 are the first choice for iMCD (van Rhee et al., 2018).

Conditions linked with Castleman disease

Linked condition Notes
Kaposi sarcoma In HHV-8-associated disease
Lymphoma Higher risk, especially in HHV-8 MCD
POEMS syndrome Often occurs with a Castleman-like lymph node picture
Paraneoplastic pemphigus A severe blistering disease, mainly with UCD
Follicular dendritic cell sarcoma Can rarely arise in UCD

3. How does it look

On the body and on scans

Feature UCD MCD
Lymph nodes One enlarged node or a cluster in one area, often several centimetres Many moderately enlarged nodes in different areas
Common sites Chest (mediastinum), neck, abdomen, pelvis Neck, armpits, groin, chest and abdomen together
Liver and spleen Normal Often enlarged
Fluid None Fluid in the abdomen, around the lungs or under the skin, especially in TAFRO
PET-CT Mild to moderate tracer uptake Usually mild to moderate uptake in many nodes

Under the microscope

Pathologists describe several patterns.

Pattern Features Most common in
Hyaline vascular (hypervascular) Shrunken germinal centres, “onion-skin” layers of small lymphocytes, and blood vessels running into the centres (“lollipop” appearance) UCD
Plasmacytic Sheets of plasma cells between the follicles iMCD and HHV-8 MCD
Mixed Features of both iMCD
HHV-8-positive Plasmablasts that stain for the HHV-8 protein LANA-1 HHV-8 MCD

These changes are not unique to Castleman disease. Similar patterns can be seen in infections, autoimmune diseases and lymphoma, so doctors must rule these out (Fajgenbaum et al., 2017).

4. Symptoms

Unicentric Castleman disease

Many people have no symptoms, and the enlarged node is found by chance on a scan. Others notice:

  • A painless lump in the neck, armpit or groin
  • Cough, chest pain or breathlessness if the mass is in the chest
  • Tummy discomfort or fullness if it is in the abdomen
  • Mouth sores and blisters in the rare case of paraneoplastic pemphigus

Multicentric Castleman disease

Symptoms can range from mild to life-threatening:

  • Fever and drenching night sweats
  • Tiredness and weakness
  • Weight loss and loss of appetite
  • Swollen lymph nodes in several areas
  • Swelling of the legs or the whole body (oedema)
  • Swollen tummy from fluid or an enlarged liver and spleen
  • Shortness of breath from fluid around the lungs
  • Skin changes, such as small red-purple spots (cherry haemangiomas)
  • Numbness or tingling in the hands and feet

iMCD-TAFRO

The TAFRO form is named after its main features (Nishimura et al., 2021):

Letter Feature
T Thrombocytopenia (low platelets)
A Anasarca (severe fluid build-up throughout the body)
F Fever
R Reticulin fibrosis of the bone marrow and renal (kidney) failure
O Organomegaly (enlarged liver, spleen and lymph nodes)

TAFRO can develop over days to weeks and often needs hospital treatment.

When to seek medical advice

See a doctor about lumps that persist for more than 2-3 weeks, or about fever, night sweats and weight loss. Seek urgent help for rapidly increasing swelling, breathlessness or reduced urine output.

5. Diagnosis

Test Purpose
Lymph node biopsy Essential; the whole node or a large sample is best
Blood count Anaemia, high or low platelets
CRP and ESR Measure inflammation
Albumin, kidney and liver tests Check for organ involvement
Immunoglobulins Often raised in multicentric disease
HIV and HHV-8 tests Separate HHV-8 MCD from iMCD
Tests for autoimmune disease and infection Rule out other causes
PET-CT or CT Show how many lymph node areas are involved
Bone marrow biopsy Often in iMCD-TAFRO and when lymphoma is suspected

Diagnostic criteria for iMCD

International criteria require all three of the following (Fajgenbaum et al., 2017):

Part Requirement
Major criteria Typical lymph node changes on biopsy, and enlarged lymph nodes (1 cm or more) in at least 2 areas
Minor criteria At least 2 of 11 clinical and laboratory features, including at least 1 laboratory feature, such as high CRP, anaemia, low albumin or kidney problems
Exclusion Infections (including HHV-8), autoimmune diseases and cancers that can look similar must be ruled out

6. Treatment

Unicentric Castleman disease

Treatment Notes
Surgery Complete removal of the affected node or nodes cures most people
Watch and wait For small, symptom-free masses that cannot easily be removed
Radiotherapy, embolisation or medicines For masses that cannot be removed; may shrink them before surgery

International guidelines recommend complete surgical removal whenever it is safe (van Rhee et al., 2020).

Idiopathic multicentric Castleman disease

Treatment Notes
Siltuximab An antibody that blocks IL-6; the recommended first treatment
Tocilizumab Blocks the IL-6 receptor; used where siltuximab is unavailable
Corticosteroids Often added for severe symptoms, then reduced
Rituximab For milder disease or when IL-6 blockade does not work
Sirolimus An mTOR inhibitor; helps some people who do not respond to IL-6 blockade
Combination chemotherapy For severe or life-threatening disease that does not respond to other treatment

In a randomised trial, siltuximab controlled the disease in about a third of people, compared with none on placebo (van Rhee et al., 2014). It is approved in the US and Europe for iMCD.

HHV-8-associated MCD

Treatment Notes
Rituximab The main treatment; often very effective
Etoposide or liposomal doxorubicin Added for severe disease or Kaposi sarcoma
Antiretroviral therapy For people with HIV; essential to control the virus
Antiviral drugs Sometimes used against HHV-8

Side effects

Treatment Possible side effects
Surgery Pain, bleeding, effects depending on the site
Siltuximab or tocilizumab Infections, rash, itching, weight gain, raised cholesterol, low blood counts
Rituximab Infusion reactions, infections, rarely reactivation of hepatitis B
Corticosteroids Raised blood sugar, mood changes, weight gain, bone thinning
Chemotherapy Low blood counts, infections, nausea, hair loss

What treatment involves day to day

Part of treatment What to expect
Siltuximab A drip lasting about 1 hour every 3 weeks, usually continued long term
Blood tests Before each infusion to check blood counts and response
Surgery for UCD Often keyhole surgery; hospital stay of a few days
Hospital care for TAFRO Intensive treatment, sometimes in high-dependency care, until the illness is controlled

Castleman disease in children

Castleman disease is uncommon in children. When it does occur, it is usually unicentric and is most often found in the neck, chest or abdomen. Surgery is usually curative.

Multicentric disease in children is rare. It is treated in a similar way to adults, with care from a paediatric haematology team.

7. Outlook (prognosis)

Type Outlook
UCD Excellent; most people are cured by surgery and survival is close to normal
iMCD Variable; many people do well on long-term treatment, but some have severe disease
iMCD-TAFRO Can be life-threatening without prompt treatment; many recover with intensive care
HHV-8 MCD Much improved since rituximab and effective HIV treatment

In older studies, about two-thirds to three-quarters of people with multicentric disease were alive 5 years after diagnosis. Outcomes are now improving with IL-6 blockade and better recognition of the disease (Dispenzieri and Fajgenbaum, 2020).

Factors linked with a poorer outlook in multicentric disease

  • The TAFRO form, especially with kidney failure or severe fluid build-up
  • Low platelets and low albumin
  • Older age and other serious illnesses
  • No response to first treatment
  • Development of lymphoma or Kaposi sarcoma

8. Follow-up

Follow-up Purpose
Clinic review Every few months at first, then less often for UCD
Blood tests CRP, blood count, albumin and kidney function to track activity
Scans CT or PET-CT to check node size and response
Lymphoma watch New or fast-growing nodes may need another biopsy

9. Living with Castleman disease

  • Keep infusion appointments; stopping IL-6 blockade can cause relapse
  • Report fever early, as infections can be more serious on treatment
  • Stay up to date with vaccinations, avoiding live vaccines while on treatment unless advised
  • Track your symptoms, such as fevers, sweats and swelling
  • Bring a list of your medicines to every appointment, as some interact with IL-6 blockers
  • Rest when you need to; fatigue is common, especially during flares
  • Connect with patient networks, such as the Castleman Disease Collaborative Network
  • Consider registry and research participation; it helps improve care for a rare disease

10. Frequently asked questions

Question Answer
Is Castleman disease cancer? No, but it is treated by haematologists and can be serious
Is it contagious? No. HHV-8 is a virus, but Castleman disease itself is not passed on by contact
Is it inherited? No
Will I need treatment forever? UCD is usually cured by surgery; iMCD often needs long-term treatment
Can it turn into lymphoma? The risk of lymphoma is higher than average, especially in HHV-8 MCD
Why did the diagnosis take so long? It is rare and its symptoms overlap with infections, autoimmune diseases and lymphoma
Can UCD come back after surgery? Rarely, if the whole mass was removed
Can I live a normal life with iMCD? Many people lead full lives while on long-term treatment, with regular check-ups
Can I get pregnant while on treatment? Discuss this with your team first; some treatments need to be paused or changed

11. Questions to ask your care team

  • Do I have unicentric or multicentric disease?
  • Has HHV-8 been tested?
  • Can the affected node be removed surgically?
  • Is siltuximab available to me?
  • How will we know if the treatment is working?
  • What symptoms should make me contact the team urgently?

Resources

  1. Dispenzieri, A. and Fajgenbaum, D.C. (2020) ‘Overview of Castleman disease’, Blood, 135(16), pp. 1353-1364.
  2. Fajgenbaum, D.C. et al. (2017) ‘International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease’, Blood, 129(12), pp. 1646-1657.
  3. Nishimura, Y. et al. (2021) ‘Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease’, American Journal of Hematology, 96(10), pp. 1241-1252.
  4. van Rhee, F. et al. (2014) ‘Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial’, Lancet Oncology, 15(9), pp. 966-974.
  5. van Rhee, F. et al. (2018) ‘International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease’, Blood, 132(20), pp. 2115-2124.
  6. van Rhee, F. et al. (2020) ‘International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease’, Blood Advances, 4(23), pp. 6039-6050.
  7. National Cancer Institute (2026) Drugs Approved for Multicentric Castleman Disease. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/multicentric-castleman-disease (Accessed: October 2026).

Prepared by the editorial team, October 2026.